**SUPPLEMENT TO:**

**Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *HLA* Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update**

Elizabeth J. Phillips1, Chonlaphat Sukasem2,3, Michelle Whirl-Carrillo4, Daniel J. Müller5,6, Henry M. Dunnenberger7, Wasun Chantratita8,9, Barry Goldspiel10, Yuan-Tsong Chen11,12, Bruce C. Carleton13, Alfred L. George, Jr.14, Taisei Mushiroda15, Teri Klein4, Roseann S. Gammal16,17, Munir Pirmohamed18

1 Vanderbilt University Medical Center, Nashville, TN, USA

2 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

3 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand

4 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA

5 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada

6 Department of Psychiatry and Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada

7 Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, IL, USA

8 Virology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

9 Center for Medical Genomics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

10 Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA

11 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

12 Department of Pediatrics, Duke University Medical Center, Durham, NC, USA

13 Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, and BC Children’s Hospital Research Institute, Vancouver, BC, Canada

14 Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

15 Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Science, Yokohama, Japan

16 Department of Pharmacy Practice, MCPHS University, Boston, MA, USA

17 Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA

18 Department of Pharmacology, University of Liverpool, Liverpool, UK

**TABLE OF CONTENTS**

[GUIDELINE UPDATES 3](#_Toc494781264)

[UPDATES IN SUPPLEMENT 3](#_Toc494781265)

[LITERATURE REVIEW 3](#_Toc494781266)

[OTHER CONSIDERATIONS 4](#_Toc494781267)

[*Allele Frequency vs. Allele Carriage Rate* 4](#_Toc494781268)

[*Proposed Mechanism for HLA-B\*15:02-mediated SJS/TEN in Response to Carbamazepine* 5](#_Toc494781269)

[*HLA-B75 Serotype* 5](#_Toc494781270)

[*Other Aromatic Anticonvulsants* 6](#_Toc494781271)

[*Available Genetic Test Options and Interpretation* 6](#_Toc494781272)

[LEVELS OF EVIDENCE 7](#_Toc494781273)

[STRENGTH OF RECOMMENDATIONS 8](#_Toc494781274)

[RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT 8](#_Toc494781275)

[SUPPLEMENTAL TABLE S1. EVIDENCE LINKING *HLA-B\*15:02* GENOTYPE WITH CARBAMAZEPINE- AND OXCARBAZEPINE-INDUCED CUTANEOUS ADVERSE REACTIONS 10](#_Toc494781276)

[SUPPLEMENTAL TABLE S2. EVIDENCE LINKING *HLA-A\*31:01* GENOTYPE WITH CARBAMAZEPINE- AND OXCARBAZEPINE-INDUCED CUTANEOUS ADVERSE REACTIONS 17](#_Toc494781277)

[REFERENCES 26](#_Toc494781278)

# GUIDELINE UPDATES

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *HLA* genotype and use of carbamazepine and oxcarbazepine is published in full on the CPIC website (<http://cpicpgx.org>) and the PharmGKB website ([www.pharmgkb.org](http://www.pharmgkb.org)). Information will be reviewed periodically and updated guidelines published online.

# UPDATES IN SUPPLEMENT

* Updated literature search from January 2013 to June 2016 for *HLA-B\*15:02* and carbamazepine.
* Expanded literature search to include *HLA-A\*31:01* and oxcarbazepine.
* Updated evidence linking *HLA-B\*15:02* to carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
* Added evidence linking *HLA-B\*15:02* to oxcarbazepine-induced SJS/TEN and evidence linking *HLA-A\*31:01* to carbamazepine-induced SJS/TEN, drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE).
* Added a section on the proposed mechanism for carbamazepine-induced SJS/TEN in *HLA-B\*15:02* positive patients.
* Added resources to facilitate incorporation of *HLA* genotype results into electronic health records with clinical decision support and updated allele frequency information (see <https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/>).

# LITERATURE REVIEW

A search was conducted on the PubMed database (1966 to June 17, 2016) for keywords ([HLA] AND [carbamazepine]), ([HLA] AND [oxcarbazepine]), ([HLA] AND [eslicarbazepine]), and ([HLA] AND [lamotrigine]). The ([HLA] AND [carbamazepine]) search yielded 238 articles, the ([HLA] AND [oxcarbazepine]) search yielded 14 articles, the ([HLA] AND [eslicarbazepine]) search yielded two articles, and the ([HLA] AND [lamotrigine]) search yielded 30 articles. Study inclusion criteria included publications that explored the association between *HLA-B\*15:02* or *HLA-A\*31:01* genotypes and severe cutaneous adverse drug reactions with any of the aforementioned antiepileptics. Non-English manuscripts were excluded. Following application of these inclusion criteria, 82 publications were reviewed.

A table of frequencies of the *HLA-B\*15:02* and *HLA-A\*31:01* alleles in different ethnic populations around the world was assembled from several sources (see ***HLA-A* and *HLA-B* Allele Frequency Table** online). Frequencies were included from the Allele Frequencies in Worldwide Populations website (<http://www.allelefrequencies.net/>), which lists frequency data for *HLA* alleles from over 200 different samples and populations. Allele frequencies were also obtained by conducting a search of the PubMed database (2000 to 2016) using the following criteria: ([HLA-B\*1502] AND [frequency]) and ([HLA-A\*3101] AND [frequency]). Studies from both sources were considered for inclusion if the following criteria were met: 1) the ethnicity of the population was clearly indicated; 2) allele frequencies were reported; and 3) the sample population consisted of at least 100 individuals.

# OTHER CONSIDERATIONS

## *Allele Frequency vs. Allele Carriage Rate*

Representation of *HLA* in a given population can be described in terms of either allele frequency (the total number of copies of the allele in the relevant population), or by allele carriage rate (the percentage of individuals who have the allele in the population or prevalence). This concept differs from other genes because *HLA* is inherited in a co-dominant fashion and to take into account those who are homozygous or have two copies of a given *HLA* allele. The representation of homozygosity in any given population may have been driven by a number of evolutionary factors that select against this (“the heterozygous advantage”) ([1](#_ENREF_1), [2](#_ENREF_2)). For carbamazepine-induced SJS/TEN and abacavir hypersensitivity, there is no current evidence to suggest a gene-dose effect or that carrying more than one copy of the *HLA* risk allele is associated with a higher risk; however, for some other phenotypes (e.g., dapsone hypersensitivity and *HLA-B\*13:01*), being homozygous portends a higher risk of disease ([3](#_ENREF_3)).

## *Proposed Mechanism for HLA-B\*15:02-mediated SJS/TEN in Response to Carbamazepine*

Current research suggests that carbamazepine binds non-covalently to the B pocket of the HLA-B\*15:02 peptide binding groove and that the B pocket residues Arg62, Asn63, Ile95, and Leu156 contribute to drug-HLA interactions ([4](#_ENREF_4)). Other members of the B75 serotype implicated in carbamazepine SJS/TEN (as described in the following section) also share these B pocket residues. However, other mechanisms by which carbamazepine and its metabolites bind to the HLA molecules cannot be discounted and may account for differences in the presentation of clinical symptoms between different patients ([5](#_ENREF_5)).

T-cell receptor (TCR) sequencing of blister-fluid derived T cells from patients with *HLA-B\*15:02*-associated carbamazepine SJS/TEN has identified a shared CD8+ TCR clonotype that bears a common CDR3 sequence that is found in the peripheral blood of carbamazepine SJS/TEN patients but not in peripheral blood of drug tolerant controls or in blister fluid from patients with SJS/TEN secondary to another drug. Thus, although the crystal structure of HLA-B\*15:02 bound to peptide drug and TCR has not been solved and the role of a peptide remains to be determined, the immunopathogenesis of *HLA-B\*15:02*-associated carbamazepine SJS/TEN likely depends upon the concomitant involvement of both a specific HLA allotype and a specific TCR clonotype ([6](#_ENREF_6)).

## *HLA-B75 Serotype*

Relevant to the proposed mechanism for *HLA-B\*15:02*-associated carbamazepine SJS/TEN, HLA molecules of the same B75 serotype (e.g., HLA-B\*15:08, HLA-B\*15:11 and HLA-B\*15:21) with similar peptide binding properties have also been associated with carbamazepine SJS/TEN, particularly HLA-B\*15:11 in populations such as Japanese and Koreans where HLA-B\*15:02 is less prevalent ([7-9](#_ENREF_7)). Currently, carbamazepine-induced SJS/TEN has not been associated with less frequently carried B75 serotype alleles such as *HLA-B\*15:30* and *HLA-B\*15:31*; however, given the structural similarity and shared peptide binding properties, the risk for this should also be considered. If a patient developed SJS/TEN despite a negative *HLA-B\*15:02* and/or *HLA-A\*31:01* result, full *HLA-B* typing may provide further insight, particularly if the test reveals the presence of another B75 serotype allele.

## *Other Aromatic Anticonvulsants*

Several drugs structurally similar to carbamazepine and oxcarbazepine have also been associated with drug-induced cutaneous adverse reactions in *HLA-B\*15:02* positive patients or are thought to be associated with greater risk, including phenytoin, eslicarbazepine acetate, and lamotrigine. For a detailed discussion of *HLA-B\*15:02* and phenytoin, please refer to the previously published CPIC guideline ([10](#_ENREF_10)). Eslicarbazepine acetate is an antiepileptic drug used in Europe and America. It is a prodrug which is activated to (S)-licarbazepine, an active metabolite of oxcarbazepine. As of this report, there have been no cases reported of eslicarbazepine-induced cutaneous adverse reactions associated with *HLA-B\*15:02*; however, based on its structural similarity to oxcarbazepine, caution should be used in patients positive for *HLA-B\*15:02*. Lamotrigine has also been associated with SJS/TEN, particularly with rapid dose escalation or when used in combination with valproic acid. A 2015 meta-analysis involving four studies in Han Chinese patients found a statistical association between *HLA-B\*15:02* and lamotrigine-induced SJS/TEN, with an odds ratio of 4.98 ([11](#_ENREF_11)).

## 

## *Available Genetic Test Options and Interpretation*

Commercially available genetic testing options change over time. Information that may assist in evaluating options is available below. Furthermore, the Genetic Testing Registry (GTR) provides a central location for voluntary submission of genetic test information by providers and is available at <http://www.ncbi.nlm.nih.gov/gtr/>.

*HLA* alleles are extremely diverse and typically consist of numerous nucleotide and resultant amino acid substitutions. Comparison of nucleotide sequences for a reference *HLA-B* allele with that of *HLA-B\*15:02* reveals 42 differences within the open reading frame of the gene (**Supplemental Figure S1**). These nucleotide sequence differences translate to a peptide exhibiting 27 amino acid substitutions in the variant allele (**Supplemental Figure S2**). Comparison of the *HLA-A\*31:01* allele with the reference *HLA-A\*01:01* reveals 46 differences within the open reading frame of the gene (**Supplemental Figure S3**). These nucleotide sequence differences translate to a peptide exhibiting 33 amino acid substitutions in the variant allele (**Supplemental Figure S4**).

A variety of companies provide clinical testing services for the detecting of *HLA-B\*15:02* and *HLA-A\*31:01*. They primarily employ two different detection methods. One is direct sequencing of the gene. Alleles are assigned by comparison of the sequence to the known variants that define *HLA-B\*15:02* or *HLA-A\*31:01* and reported as the diplotype of *HLA-B* or *HLA-A* alleles, respectively.

Genotyping is another common approach in which the sequence variants that define *HLA-B\*15:02* and *HLA-A\*31:01* are directly detected through a panel of DNA tests. Allele specific polymerase chain reaction (PCR) is commonly employed where PCR primers specific for each nucleotide variant are used. The PCR products can then be detected using gel electrophoresis or other methods. A variety of other genotyping methods may also be used to directly detect each of the nucleotide variants for *HLA-B\*15:02* and *HLA-A\*31:01.* As the test is specific for *HLA-B\*15:02* or *HLA-A\*31:01*, the test will only report its presence or absence as opposed to the full diplotype available through sequencing.

Another option is the genotyping of one or more single nucleotide polymorphisms (SNPs) that are near the *HLA-B* locus and in linkage disequilibrium with the *HLA-B\*15:02* allele. However, as this test is indirect and depends upon linkage disequilibrium which may vary between different populations, it may have lower accuracy. It also requires genotyping and may not be any faster or less expensive than genotyping of the specific defining variants.

# LEVELS OF EVIDENCE

The evidence summarized in **Supplemental Tables S1 and S2** is graded on a scale of high, moderate, and weak, based upon level of evidence:

**High**: Evidence includes consistent results from well-designed, well-conducted studies.

**Moderate**: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence.

**Weak**: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.

Based on the levels of evidence for major findings, the strength of therapeutic recommendations are assigned accordingly (**Tables 2 and 3, main manuscript**).

# STRENGTH OF RECOMMENDATIONS

CPIC uses a slight modification of a transparent and simple system for recommendations adopted from the rating scale for evidence-based recommendations on the use of antiretroviral agents ([12](#_ENREF_12)):

**Strong**: The evidence is high quality and the desirable effects clearly outweigh the undesirable effects.

**Moderate**: There is a close or uncertain balance as to whether the evidence is high quality and the desirable effects clearly outweigh the undesirable effects.

**Optional**: The desirable effects are closely balanced with undesirable effects, or the evidence is weak or based on extrapolations. There is room for differences in opinion as to the need for the recommended course of action.

**No recommendation**: There is insufficient evidence, confidence, or agreement to provide a recommendation to guide clinical practice at this time.

# RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT

Clinical decision support (CDS) tools integrated into electronic health records (EHRs) can help guide the optimal use of pharmacogenetic test results at the point of care ([13-17](#_ENREF_13)). Please refer to the CPIC website for this guideline (<https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/>) for resources to support the adoption of this guideline’s recommendations into an EHR. Based on the capabilities of various EHRs and local preferences, we recognize that approaches may vary across organizations. Our intent is to synthesize foundational knowledge that provides a common starting point for incorporating the use of *HLA* genotype results to guide the rational use of carbamazepine and oxcarbazepine in an EHR.

Effectively incorporating pharmacogenetic information into an EHR to optimize drug therapy should have some key attributes. Pharmacogenetic results, an interpreted phenotype, and a concise interpretation or summary of the result must be documented in the EHR ([18](#_ENREF_18), [19](#_ENREF_19)). To incorporate a phenotype in the EHR in a standardized manner, genotype test results provided by the laboratory must be consistently translated into an interpreted phenotype (**Table 1, main manuscript**). Because clinicians must be able to easily find the information, the interpreted phenotype may be documented as a problem list entry, in a patient summary section, or in the adverse drug reaction section; these phenotypes are best stored in the EHR at the “person level” that links to both the inpatient and outpatient record rather than at the date-centric “encounter level.” Additionally, results should be entered as standardized and discrete terms to facilitate using them to provide point-of-care CDS ([13](#_ENREF_13), [20](#_ENREF_20)).

Because pharmacogenetic results have lifetime implications of clinical significance that may expand as more knowledge becomes available, results should be placed into a section of the EHR that is accessible independent of the test result date to allow clinicians to quickly find the result at any time after it is initially placed in the EHR. To facilitate this process, CPIC provides gene-specific figures and tables that illustrate how *HLA* pharmacogenetic test results could be entered into an EHR, example EHR consultation/genetic test interpretation language, and widely used nomenclature systems for genes and drugs relevant to the guideline

(see the following online resources: ***HLA-B* Genotype Table**, ***HLA-A* Genotype Table**, ***HLA* Gene Resource Mappings Table**, **Carbamazepine Drug Resource Mappings Table**, and **Oxcarbazepine Drug Resource Mappings Table**).

Point-of-care CDS should be designed to effectively notify clinicians of prescribing implications at any time after the test result is entered into the EHR. CPIC also provides gene-drug specific tables and example pre- and post-alert language that provide guidance to achieve these objectives with diagrams that illustrate how point-of-care CDS should be entered into the EHR (see the following online resources: **Carbamazepine Pre- and Post-test Alerts and Flow Charts** and **Oxcarbazepine Pre-and Post-test Alerts and Flow Charts**).

# **TABLE S1. EVIDENCE LINKING *HLA-B\*15:02* GENOTYPE WITH CARBAMAZEPINE- AND OXCARBAZEPINE-INDUCED CUTANEOUS ADVERSE REACTIONS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of Experimental Model** | **Clinical Phenotype** | **Major Findings** | **References** | **Level of Evidencea** |
| **Carbamazepine and *HLA-B\*15:02*** | | | | |
| In vitro | N/A | PBMCs from carbamazepine-induced SJS/TEN patients, all HLA-B\*15:02 positive, have significantly higher levels of interferon gamma and granulysin when cultured with carbamazepine, compared to carbamazepine-tolerant patients (2 HLA-B\*15:02 positive and 9 HLA-B\*15:02 negative). | Ko, *et al.* 2011 ([21](#_ENREF_21)) | Moderate |
| In vitro | SJS/TEN | Patients with carbamazepine-induced SJS/TEN and HLA-B\*15:02 positive mounted a cytotoxic T lymphocyte response. This response was absent in carbamazepine-tolerant HLA-B\*15:02 positive patients. | Wei, *et al.* 2012 ([4](#_ENREF_4)) | Moderate |
| Clinical | SJS/TEN | Prospective screening of *HLA-B\*15:02* reduces the incidence of carbamazepine-induced SJS/TEN compared to historical data. | Chen, *et al.* 2011 ([22](#_ENREF_22))  Chen, *et al.* 2014 ([23](#_ENREF_23)) | High |
| Clinical | SJS/TEN | Significant association between *HLA-B\*15:02* genotype and patients with carbamazepine-induced SJS/TEN compared to carbamazepine-tolerant patients and/or healthy controls. | **Supports statement:**  Chung, *et al.* 2004 ([24](#_ENREF_24))  Hung, *et al.* 2006 ([25](#_ENREF_25))  Man, *et al.* 2007 ([26](#_ENREF_26))  Locharernkul, *et al.* 2008 ([27](#_ENREF_27))  Mehta, *et al.* 2009 ([28](#_ENREF_28))  Tassaneeyakul, *et al.* 2010 ([7](#_ENREF_7))  Wu, *et al.* 2010 ([29](#_ENREF_29))  Chang, *et al.* 2011 ([30](#_ENREF_30))  Then, *et al.* 2011 ([31](#_ENREF_31))  Wang, *et al.* 2011 ([32](#_ENREF_32))  Zhang, *et al.* 2011 ([33](#_ENREF_33))  Kulkantrakorn, *et al.* 2012 ([34](#_ENREF_34))  Shi, *et al.* 2012 ([35](#_ENREF_35))  Neuman, *et al.* 2012 ([36](#_ENREF_36))  Amstutz, *et al.* 2013 ([37](#_ENREF_37))  He, *et al.* 2013 ([38](#_ENREF_38))  Cheung, *et al.* 2013 ([39](#_ENREF_39))  Lin, *et al.* 2013 ([40](#_ENREF_40))  Aggarwal, *et al.* 2014 ([41](#_ENREF_41))  Chong, *et al.* 2014 ([42](#_ENREF_42))  Khor, *et al.* 2014 ([43](#_ENREF_43))  Kwan, *et al.* 2014 ([44](#_ENREF_44))  Sun, *et al.* 2014 ([45](#_ENREF_45))  Genin, *et al.* 2014 ([46](#_ENREF_46))  Hsiao, *et al.* 2014 ([47](#_ENREF_47))  Toh, *et al.* 2014 ([48](#_ENREF_48))  Wang, *et al.* 2014 ([49](#_ENREF_49))  Nguyen, *et al.* 2015 ([50](#_ENREF_50))  Yang, *et al.* 2015 ([51](#_ENREF_51))  Teh, *et al.* 2016 ([52](#_ENREF_52))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Alfirevic, *et al.* 2006 ([53](#_ENREF_53))  Kashiwagi, *et al.* 2008 ([54](#_ENREF_54))  Kaniwa, *et al.* 2008 ([55](#_ENREF_55))  Kano, *et al.* 2008 ([56](#_ENREF_56))  Ikeda, *et al.* 2010 ([57](#_ENREF_57))  Kaniwa, *et al.* 2010 ([8](#_ENREF_8))  Kim, *et al.* 2011 ([9](#_ENREF_9))  Niihara, *et al.* 2012 ([58](#_ENREF_58))  Park, *et al.* 2016 ([59](#_ENREF_59)) | High |
| Clinical | DRESS/MPE | No significant association between *HLA-B\*15:02* genotype and patients with carbamazepine-induced **non-SJS/TEN cutaneous adverse drug reaction** compared to carbamazepine-tolerant patients and/or healthy controls. | Alfirevic, *et al.* 2006 ([53](#_ENREF_53))  Hung, *et al.* 2006 ([25](#_ENREF_25))  Man, *et al.* 2007 ([26](#_ENREF_26))  Kashiwagi, *et al.* 2008 ([54](#_ENREF_54))  Kano, *et al.* 2008 ([56](#_ENREF_56))  Ikeda, *et al.* 2010 ([57](#_ENREF_57))  Wu, *et al.* 2010 ([29](#_ENREF_29))  Wang, *et al.* 2011 ([32](#_ENREF_32))  Niihara, *et al.* 2012 ([58](#_ENREF_58))  Amstutz, *et al.* 2013 ([37](#_ENREF_37))  Li, *et al.* 2013 ([60](#_ENREF_60))  Lin, *et al.* 2013 ([40](#_ENREF_40))  Sun, *et al.* 2014 ([45](#_ENREF_45))  Hsiao, *et al.* 2014 ([47](#_ENREF_47))  Locharernkul, *et al.* 2008 ([27](#_ENREF_27))  Chong, *et al.* 2014 ([42](#_ENREF_42))  Nguyen, *et al.* 2015 ([50](#_ENREF_50)) | High |
| Clinical | SJS/TEN | Cases of patients with carbamazepine-induced SJS/TEN and *HLA-B\*15:02* genotype. | Lonjou, *et al.* 2006 ([61](#_ENREF_61))  Odueyungbo, *et al.* 2010 ([62](#_ENREF_62))  Elzagallaai, *et al.* 2011 ([63](#_ENREF_63))  Wang, *et al.* 2012 ([64](#_ENREF_64))  Techasatian, *et al.* 2015 ([65](#_ENREF_65))  Tan, *et al.* 2015 ([66](#_ENREF_66))  Bellon, *et al.* 2016 ([67](#_ENREF_67)) | Moderate |
| **Oxcarbazepine and *HLA-B\*15:02*** | | | | |
| Clinical | SJS/TEN | Significant association between *HLA-B\*15:02* genotype and patients with oxcarbazepine-induced SJS/TEN compared to oxcarbazepine-tolerant patients or healthy controls. | **Supports statement:**  Chen, *et al.* 2017 ([68](#_ENREF_68))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Amstutz, *et al.* 2013 ([37](#_ENREF_37)) | High |
| Clinical | DRESS/MPE | No significant association between *HLA-B\*15:02* genotype and patients with oxcarbazepine-induced **non-SJS/TEN cutaneous adverse drug reaction** compared to oxcarbazepine-tolerant patients and/or healthy controls. | **Supports statement:**  Hu, *et al.* 2011 ([69](#_ENREF_69))  He, *et al.* 2012 ([70](#_ENREF_70))  Lv, *et al.* 2013 ([71](#_ENREF_71))  Sun, *et al.* 2014 ([45](#_ENREF_45))  Wang, *et al.* 2014 ([72](#_ENREF_72))  Chen, *et al.* 2017 ([68](#_ENREF_68))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Amstutz, *et al.* 2013 ([37](#_ENREF_37)) | High |
| Clinical | SJS/TEN | Cases of patients with oxcarbazepine-induced SJS/TEN and *HLA-B\*15:02* genotype. | Chen, *et al.* 2009 ([73](#_ENREF_73))  Hung, *et al.* 2010 ([74](#_ENREF_74))  Sun, *et al.* 2014 ([45](#_ENREF_45)) | Moderate |
| Clinical | DRESS | Case of a patient with oxcarbazepine-induced DRESS and *HLA-B\*15:02* genotype. | Shankarkumar, *et al.* 2009 ([75](#_ENREF_75)) | Weak |
| Clinical | MPE | Cases of patients with oxcarbazepine-induced MPE and *HLA-B\*15:02* genotype. | Wang, *et al.* 2012 ([64](#_ENREF_64))  Wang, *et al.* 2014 ([72](#_ENREF_72)) | Weak |

DRESS: drug reaction with eosinophilia and systemic symptoms; MPE: maculopapular exanthema; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis

aRating scheme described in the **Supplemental Material**.

# **TABLE S2. EVIDENCE LINKING *HLA-A\*31:01* GENOTYPE WITH CARBAMAZEPINE- AND OXCARBAZEPINE-INDUCED CUTANEOUS ADVERSE REACTIONS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of Experimental Model** | **Clinical Phenotype** | **Major Findings** | **References** | **Level of Evidencea** |
| **Carbamazepine and *HLA-A\*31:01*** | | | | |
| In vitro | N/A | HLA-A\*31:01 restricted the activation of carbamazepine-specific CD8(+) T-cells that were derived from a patient with *HLA-A\*31:01* genotype who presented with a generalized maculopapular exanthema with eosinophilia and lymphocytosis 6 days after starting carbamazepine. | Lichtenfels, *et al.* 2014 ([76](#_ENREF_76)) | Weak |
| Clinical | DRESS | Significant association between *HLA-A\*31:01* genotype and patients with carbamazepine-induced DRESS compared to carbamazepine-tolerant patients and/or healthy controls. | **Supports statement:**  Hung, *et al.* 2006 ([25](#_ENREF_25))  Kashiwagi, *et al.* 2008 ([54](#_ENREF_54))  Kim, *et al.* 2011 ([9](#_ENREF_9))  McCormack, *et al.* 2011 ([77](#_ENREF_77))  Ozeki, *et al.* 2011 ([78](#_ENREF_78))  Niihara, *et al.* 2012 ([58](#_ENREF_58))  Amstutz, *et al.* 2013 ([37](#_ENREF_37))  Genin, *et al.* 2014 ([46](#_ENREF_46))  Hsiao, *et al.* 2014 ([47](#_ENREF_47))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Shirzadi, *et al.* 2015 ([79](#_ENREF_79)) | High |
| Clinical | MPE | Significant association between *HLA-A\*31:01* genotype and patients with carbamazepine-induced MPE compared to carbamazepine-tolerant patients and/or healthy controls. | **Supports statement:**  Hung, *et al.* 2006 ([25](#_ENREF_25))  Kashiwagi, *et al.* 2008 ([54](#_ENREF_54))  Hsiao, *et al.* 2014 ([47](#_ENREF_47))  McCormack, *et al.* 2011 ([77](#_ENREF_77))  Ozeki, *et al.* 2011 ([78](#_ENREF_78))  Niihara, *et al.* 2012 ([58](#_ENREF_58))  Amstutz, *et al.* 2013 ([37](#_ENREF_37))  Fricke-Galindo, *et al.* 2014 ([80](#_ENREF_80))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Li, *et al.* 2013 ([60](#_ENREF_60))  Song, *et al.* 2014 ([81](#_ENREF_81))  Shirzadi, *et al.* 2015 ([79](#_ENREF_79)) | Moderate |
| Clinical | SJS/TEN | Significant association between *HLA-A\*31:01* genotype and patients with carbamazepine-induced SJS/TEN compared to carbamazepine-tolerant patients. | **Supports statement:**  Ozeki, *et al.* 2011 ([78](#_ENREF_78))  McCormack, *et al.* 2011 ([77](#_ENREF_77))  Genin, *et al.* 2014 ([46](#_ENREF_46))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Hung, *et al.* 2006 ([25](#_ENREF_25))  Kim, *et al.* 2011 ([9](#_ENREF_9))  Niihara, *et al.* 2012 ([58](#_ENREF_58))  Shi, *et al.* 2012 ([35](#_ENREF_35))  Amstutz, *et al.* 2013 ([37](#_ENREF_37))  Genin, *et al.* 2014 ([46](#_ENREF_46))  Hsiao, *et al.* 2014 ([47](#_ENREF_47))  Park, *et al.* 2016 ([59](#_ENREF_59)) | High |
| Clinical | DRESS | Cases of patients with carbamazepine-induced DRESS and *HLA-A\*31:01* genotype. | Mizumoto, *et al.* 2012 ([82](#_ENREF_82))  Anjum, *et al.* 2014 ([83](#_ENREF_83))  Segert, *et al.* 2016 ([84](#_ENREF_84)) | Weak |
| **Oxcarbazepine and *HLA-A\*31:01*** | | | | |
| Clinical | DRESS/MPE | No significant association between *HLA-A\*31:01* genotype and patients with oxcarbazepine-induced non-SJS/TEN cutaneous adverse drug reaction compared to oxcarbazepine-tolerant patients or healthy controls. | **Supports statement:**  Chen, *et al.* 2017 ([68](#_ENREF_68))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Amstutz, *et al.* 2013 ([37](#_ENREF_37)) | Moderate |
| Clinical | SJS/TEN | No significant association between *HLA-A\*31:01* genotype and patients with oxcarbazepine-induced SJS/TEN compared to oxcarbazepine-tolerant patients or healthy controls. | **Supports statement:**  Chen, *et al.* 2017 ([68](#_ENREF_68))  **Indeterminate (inadequate statistical power to detect low frequency variant):**  Amstutz, *et al.* 2013 ([37](#_ENREF_37)) | High |

DRESS = drug reaction with eosinophilia and systemic symptoms; MPE = maculopapular exanthema; SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis

aRating scheme described in the **Supplemental Material**

HLA-B Reference ATGCTGGTCATGGCGCCCCGAACCGTCCTCCTGCTGCTCTCGGCGGCCCTGGCCCTGACCGAGACCTGGGCCGGCTCCCACTCCATGAGGTATTTCTACA

HLA-B\*1502 ATGC**G**GGTCA**C**GGCGCCCCGAACCGTCCTCCTGCTGCTCTCGG**GA**GCCCTGGCCCTGACCGAGACCTGGGCCGGCTCCCACTCCATGAGGTATTTCTACA

HLA-B Reference CCTCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACGTGGACGACACCCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCC

HLA-B\*1502 CC**G**CC**A**TGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATC**G**CAGTGGGCTACGTGGACGACACCCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCC

HLA-B Reference GAGAGAGGAGCCGCGGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTACAAGGCCCAGGCACAGACTGACCGAGAG

HLA-B\*1502 GAG**GAT**GG**C**GCC**C**CGGGCGCC**A**TGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCT**C**CAAG**A**CC**A**A**CA**CACAGACT**T**ACCGAGAG

HLA-B Reference AGCCTGCGGAACCTGCGCGGCTACTACAACCAGAGCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGGCGCCTCC

HLA-B\*1502 AGCCTGCGGAACCTGCGCGGCTACTACAACCAGAGCGAGGCCGGGTCTCACA**T**C**A**TCCAGAG**G**ATGTA**T**GGCTGCGACGTGGGGCCGGACGGGCGCCTCC

HLA-B Reference TCCGCGGGCATGACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGCGCTCCTGGACCGCCGCGGACACGGCGGCTCAGATCAC

HLA-B\*1502 TCCGCGGG**T**ATGACCAGT**C**CGCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTG**A**GCTCCTGGACCGC**G**GCGGACACGGCGGCTCAGATCAC

HLA-B Reference CCAGCGCAAGTGGGAGGCGGCCCGTGAGGCGGAGCAGCGGAGAGCCTACCTGGAGGGCGAGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAG

HLA-B\*1502 CCAGCGCAAGTGGGAGGCGGCCCGTGAGGCGGAGCAGC**T**GAGAGCCTACCTGGAGGGC**CT**GTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAG

HLA-B Reference GACAAGCTGGAGCGCGCTGACCCCCCAAAGACACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGTTTCTACC

HLA-B\*1502 GA**G**A**C**GCTG**C**AGCGCGC**G**GACCCCCCAAAGACACA**T**GTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGG**C**TTCTACC

HLA-B Reference CTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGACACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAA

HLA-B\*1502 CTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGACAC**C**GAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAA

HLA-B Reference GTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCCG

HLA-B\*1502 GTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCC**A**

HLA-B Reference TCTTCCCAGTCCACCGTCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTTGTGGTCATCGGAGCTGTGGTCGCTGCTGTGATGTGTAGGA

HLA-B\*1502 TCTTCCCAGTCCACC**A**TCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTTGTGGTCATCGGAGCTGTGGTCGCT**A**CTGTGATGTGTAGGA

HLA-B Reference GGAAGAGTTCAGGTGGAAAAGGAGGGAGCTACTCTCAGGCTGCGTGCAGCGACAGTGCCCAGGGCTCTGATGTGTCTCTCACAGCTTGA

HLA-B\*1502 GGAAGAG**C**TCAGGTGGAAAAGGAGGGAGCTACTCTCAGGCTGCGT**C**CAGCGACAGTGCCCAGGGCTCTGATGTGTCTCTCACAGCTTGA

**Figure S1.** Nucleotide coding sequence alignment of *HLA-B\*15:02* and the reference sequence. Nucleotide differences between the two sequences are highlighted in blue. This alignment was generated using the IMGT/HLA Database’s alignment tool ([www.ebi.ac.uk/imgt/hla/align.html](http://www.ebi.ac.uk/imgt/hla/align.html)) and visualized in Jalview ([85](#_ENREF_85)).

HLA-B Reference MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVG

HLA-B\*1502 M**R**V**T**APRTVLLLLS**G**ALALTETWAGSHSMRYFYT**AM**SRPGRGEPRFI**A**VG

HLA-B Reference YVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRE

HLA-B\*1502 YVDDTQFVRFDSDAASPR**MA**PRAPWIEQEGPEYWDRNTQI**S**K**TNT**QT**Y**RE

HLA-B Reference SLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIAL

HLA-B\*1502 SLRNLRGYYNQSEAGSH**II**Q**R**MYGCDVGPDGRLLRG**Y**DQ**S**AYDGKDYIAL

HLA-B Reference NEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGK

HLA-B\*1502 NEDL**S**SWTAADTAAQITQRKWEAAREAEQ**L**RAYLEG**L**CVEWLRRYLENGK

HLA-B Reference DKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQ

HLA-B\*1502 **ET**L**Q**RADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQ

HLA-B Reference DTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEP

HLA-B\*1502 DTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEP

HLA-B Reference SSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACS

HLA-B\*1502 SSQST**I**PIVGIVAGLAVLAVVVIGAVVA**T**VMCRRKSSGGKGGSYSQAA**S**S

HLA-B Reference DSAQGSDVSLTA

HLA-B\*1502 DSAQGSDVSLTA

**Figure S2.** Amino acid sequence alignment of HLA-B\*15:02 and the reference sequence. Amino acid differences between the two sequences are highlighted in blue. This alignment was generated using the IMGT/HLA Database’s alignment tool ([www.ebi.ac.uk/imgt/hla/align.html](http://www.ebi.ac.uk/imgt/hla/align.html)) and visualized in Jalview ([85](#_ENREF_85)).

cDNA                       10         20         30         40         50         60         70         80         90        100   
 A\*01:01:01:01      ATGGCCGTCA TGGCGCCCCG AACCCTCCTC CTGCTACTCT **C**GGGGGCCCT GGCCCTGACC CAGACCTGGG CGGGCTCCCA CTCCATGAGG TATTTC**TT**CA   
 A\*31:01:02:01      ATGGCCGTCA TGGCGCCCCG AACCCTCCTC CTGCTACTCT **T**GGGGGCCCT GGCCCTGACC CAGACCTGGG CGGGCTCCCA CTCCATGAGG TATTTC**AC**CA   
   
 cDNA                      110        120        130        140        150        160        170        180        190        200   
 A\*01:01:01:01      CATCCGTGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCAT CGCCGTGGGC TACGTGGACG ACACGCAGTT CGTGCGGTTC GACAGCGACG CCGCGAGCCA   
 A\*31:01:02:01      CATCCGTGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCAT CGCCGTGGGC TACGTGGACG ACACGCAGTT CGTGCGGTTC GACAGCGACG CCGCGAGCCA   
   
 cDNA                      210        220        230        240        250        260        270        280        290        300   
 A\*01:01:01:01      GA**A**GATGGAG CCGCGGGCGC CGTGGATAGA GCAGGAG**G**GG CC**G**GAGTATT GGGACCAGGA GACACGGAAT **A**TGAAGGCCC ACTCACAGA**C** TGACCGAG**C**G   
 A\*31:01:02:01      GA**G**GATGGAG CCGCGGGCGC CGTGGATAGA GCAGGAG**A**GG CC**T**GAGTATT GGGACCAGGA GACACGGAAT **G**TGAAGGCCC ACTCACAGA**T** TGACCGAG**T**G   
   
 cDNA                      310        320        330        340        350        360        370        380        390        400   
 A\*01:01:01:01      AACCTGGGGA CCCTGCGCGG CTACTACAAC CAGAGCGAGG **A**CGGTTCTCA CACCATCCAG AT**A**ATGTATG GCTGCGACGT GGGG**C**CGGAC GGGCGCTTCC   
 A\*31:01:02:01      **G**ACCTGGGGA CCCTGCGCGG CTACTACAAC CAGAGCGAGG **C**CGGTTCTCA CACCATCCAG AT**G**ATGTATG GCTGCGACGT GGGG**T**CGGAC GGGCGCTTCC   
   
 cDNA                      410        420        430        440        450        460        470        480        490        500   
 A\*01:01:01:01      TCCGCGGGTA CC**G**GCAGGAC GCCTACGACG GCAAGGATTA CATCGCC**C**TG AACGAGGACC TGCGCTCTTG GACCGCGGCG GACATGGC**A**G CTCAGATCAC   
 A\*31:01:02:01      TCCGCGGGTA CC**A**GCAGGAC GCCTACGACG GCAAGGATTA CATCGCC**T**TG AACGAGGACC TGCGCTCTTG GACCGCGGCG GACATGGC**G**G CTCAGATCAC   
   
 cDNA                      510        520        530        540        550        560        570        580        590        600   
 A\*01:01:01:01      C**A**AGCGCAAG TGGGAGGCGG **T**CC**A**TG**C**GGC GGAGCAG**CG**G AGAG**T**CTACC TGGAGGGC**CG** GTGCGTGGA**C** **G**GGCTCCGCA GATACCTGGA GAACGGGAAG   
 A\*31:01:02:01      C**C**AGCGCAAG TGGGAGGCGG **C**CC**G**TG**T**GGC GGAGCAG**TT**G AGAG**C**CTACC TGGAGGGC**AC** GTGCGTGGA**G** **T**GGCTCCGCA GATACCTGGA GAACGGGAAG   
   
 cDNA                      610        620        630        640        650        660        670        680        690        700   
 A\*01:01:01:01      GAGACGCTGC AGCGCACGGA CCCCCCCAAG AC**A**CATATGA C**C**CACCAC**C**C **CA**TCTCTGAC CATGAGGCCA CCCTGAGGTG CTGGGCCCTG **G**GCTTCTACC   
 A\*31:01:02:01      GAGACGCTGC AGCGCACGGA CCCCCCCAAG AC**G**CATATGA C**T**CACCAC**G**C **TG**TCTCTGAC CATGAGGCCA CCCTGAGGTG CTGGGCCCTG **A**GCTTCTACC   
   
 cDNA                      710        720        730        740        750        760        770        780        790        800   
 A\*01:01:01:01      CTGCGGAGAT CACACTGACC TGGCAGCGGG ATGGGGAGGA CCAGACCCAG GACACGGAGC TCGTGGAGAC CAGGCCTGCA GGGGATGGAA CCTTCCAGAA   
 A\*31:01:02:01      CTGCGGAGAT CACACTGACC TGGCAGCGGG ATGGGGAGGA CCAGACCCAG GACACGGAGC TCGTGGAGAC CAGGCCTGCA GGGGATGGAA CCTTCCAGAA   
   
 cDNA                      810        820        830        840        850        860        870        880        890        900   
 A\*01:01:01:01      GTGGGCG**G**CT GTGGTGGTGC CTTCTGGA**G**A GGAGCAGAGA TACACCTGCC ATGTGCAGCA TGAGGGTCT**G** CCCAAGCCCC TCACCCTGAG ATGGGAGC**T**G   
 A\*31:01:02:01      GTGGGCG**T**CT GTGGTGGTGC CTTCTGGA**C**A GGAGCAGAGA TACACCTGCC ATGTGCAGCA TGAGGGTCT**C** CCCAAGCCCC TCACCCTGAG ATGGGAGC**C**G   
   
 cDNA                      910        920        930        940        950        960        970        980        990       1000   
 A\*01:01:01:01      TCTTCCCAGC CCACCATCCC CATCGTGGGC ATCATTGCTG GCCT**G**GTTCT C**C**TTGGAGCT GTG**A**TC**A**CTG GAGCTGTGGT CGCTGC**C**GTG A**T**GTGGAGGA   
 A\*31:01:02:01      TCTTCCCAGC CCACCATCCC CATCGTGGGC ATCATTGCTG GCCT**A**GTTCT C**T**TTGGAGCT GTG**T**TC**G**CTG GAGCTGTGGT CGCTGC**T**GTG A**G**GTGGAGGA   
   
 cDNA                     1010       1020       1030       1040       1050       1060       1070       1080       1090   
 A\*01:01:01:01      GGAAGAGCTC AGATAGAAAA GGAGGGAG**T**T AC**A**CTCAGGC TGCAAGCAGT GACAGTGCCC AGGGCTCTGA T**G**TGTCTCTC ACAGCTTGTA AAGTGTGA

A\*31:01:02:01      GGAAGAGCTC AGATAGAAAA GGAGGGAG**C**T AC**T**CTCAGGC TGCAAGCAGT GACAGTGCCC AGGGCTCTGA T**A**TGTCTCTC ACAGCTTGTA AAGTGTGA

**Figure S3.** Nucleotide coding sequence alignment of *HLA-A\*31:01* and the reference sequence (*HLA-A\*01:01*). Nucleotide differences between the two sequences are highlighted in red. This alignment was generated using the IMGT/HLA Database’s alignment tool ([www.ebi.ac.uk/imgt/hla/align.html](http://www.ebi.ac.uk/imgt/hla/align.html)) and highlighted manually.

AA Pos.                   -21        -11         -1         10         20         30         40         50         60         70   
A\*01:01:01:01            MAVM APRTLLLLL**S** GALALTQTWA GSHSMRYF**F**T SVSRPGRGEP RFIAVGYVDD TQFVRFDSDA ASQ**K**MEPRAP WIEQE**G**PEYW DQETRN**M**KAH   
A\*31:01:02:01            MAVM APRTLLLLL**L** GALALTQTWA GSHSMRYF**T**T SVSRPGRGEP RFIAVGYVDD TQFVRFDSDA ASQ**R**MEPRAP WIEQE**R**PEYW DQETRN**V**KAH   
   
AA Pos.                    80         90        100        110        120        130        140        150        160        170   
A\*01:01:01:01      SQ**T**DR**AN**LGT LRGYYNQSE**D** GSHTIQ**I**MYG CDVG**P**DGRFL RGY**R**QDAYDG KDYIALNEDL RSWTAADMAA QIT**K**RKWEA**V** **HA**AEQ**R**R**V**YL EG**R**CV**DG**LRR   
A\*31:01:02:01      SQ**I**DR**VD**LGT LRGYYNQSE**A** GSHTIQ**M**MYG CDVG**S**DGRFL RGY**Q**QDAYDG KDYIALNEDL RSWTAADMAA QIT**Q**RKWEA**A** **RV**AEQ**L**R**A**YL EG**T**CV**EW**LRR   
   
AA Pos.                   180        190        200        210        220        230        240        250        260        270   
A\*01:01:01:01      YLENGKETLQ RTDPPKTHMT HH**PI**SDHEAT LRCWAL**G**FYP AEITLTWQRD GEDQTQDTEL VETRPAGDGT FQKWA**A**VVVP SG**E**EQRYTCH VQHEGLPKPL   
A\*31:01:02:01      YLENGKETLQ RTDPPKTHMT HH**AV**SDHEAT LRCWAL**S**FYP AEITLTWQRD GEDQTQDTEL VETRPAGDGT FQKWA**S**VVVP SG**Q**EQRYTCH VQHEGLPKPL   
   
AA Pos.                   280        290        300        310        320        330        340   
A\*01:01:01:01      TLRWE**L**SSQP TIPIVGIIAG LVL**L**GAV**IT**G AVVAAV**M**WRR KSSDRKGGSY **T**QAASSDSAQ GSD**V**SLTACK V   
A\*31:01:02:01      TLRWE**P**SSQP TIPIVGIIAG LVL**F**GAV**FA**G AVVAAV**R**WRR KSSDRKGGSY **S**QAASSDSAQ GSD**M**SLTACK V

**Figure S4.** Amino acid sequence alignment of HLA-A\*31:01 and the reference sequence (HLA-A\*01:01). Amino acid differences between the two sequences are highlighted in red. This alignment was generated using the IMGT/HLA Database’s alignment tool ([www.ebi.ac.uk/imgt/hla/align.html](http://www.ebi.ac.uk/imgt/hla/align.html)) and highlighted manually.

# REFERENCES

(1) Carrington, M. *et al.* HLA and HIV-1: heterozygote advantage and B\*35-Cw\*04 disadvantage. *Science* **283**, 1748-52 (1999).

(2) Tang, J. *et al.* HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. *AIDS Res Hum Retroviruses* **15**, 317-24 (1999).

(3) Zhang, F.R. *et al.* HLA-B\*13:01 and the dapsone hypersensitivity syndrome. *N Engl J Med* **369**, 1620-8 (2013).

(4) Wei, C.Y., Chung, W.H., Huang, H.W., Chen, Y.T. & Hung, S.I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. *J Allergy Clin Immunol* **129**, 1562-9 e5 (2012).

(5) Pirmohamed, M., Ostrov, D.A. & Park, B.K. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. *J Allergy Clin Immunol* **136**, 236-44 (2015).

(6) Hung, S. Pharmaco-immunological synapse of HLA-drug TCR in SCAR. *Clinical and Translational Allergy* **6(Suppl 3)**, 183 (2016).

(7) Tassaneeyakul, W. *et al.* Association between HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. *Epilepsia* **51**, 926-30 (2010).

(8) Kaniwa, N. *et al.* HLA-B\*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. *Epilepsia* **51**, 2461-5 (2010).

(9) Kim, S.H. *et al.* Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. *Epilepsy Res* **97**, 190-7 (2011).

(10) Caudle, K.E. *et al.* Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clin Pharmacol Ther* **96**, 542-8 (2014).

(11) Zeng, T., Long, Y.S., Min, F.L., Liao, W.P. & Shi, Y.W. Association of HLA-B\*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. *Int J Dermatol* **54**, 488-93 (2015).

(12) Long, R.M. Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH Pharmacogenetics Research Network. *Clin Pharmacol Ther* **81**, 450-4 (2007).

(13) Shuldiner, A.R. *et al.* The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clin Pharmacol Ther* **94**, 207-10 (2013).

(14) Wilke, R.A. *et al.* The emerging role of electronic medical records in pharmacogenomics. *Clin Pharmacol Ther* **89**, 379-86 (2011).

(15) Peterson, J.F. *et al.* Electronic health record design and implementation for pharmacogenomics: a local perspective. *Genet Med* **15**, 833-41 (2013).

(16) Gottesman, O. *et al.* The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. *Genet Med* **15**, 761-71 (2013).

(17) Kullo, I.J., Jarvik, G.P., Manolio, T.A., Williams, M.S. & Roden, D.M. Leveraging the electronic health record to implement genomic medicine. *Genet Med* **15**, 270-1 (2013).

(18) Hicks, J.K. *et al.* A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. *Clin Pharmacol Ther* **92**, 563-6 (2012).

(19) Hoffman, J.M. *et al.* Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *J Am Med Inform Assoc* **23**, 796-801 (2016).

(20) Pulley, J.M. *et al.* Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. *Clin Pharmacol Ther* **92**, 87-95 (2012).

(21) Ko, T.M. *et al.* Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. *J Allergy Clin Immunol* **128**, 1266-76 e11 (2011).

(22) Chen, P. *et al.* Carbamazepine-induced toxic effects and HLA-B\*1502 screening in Taiwan. *N Engl J Med* **364**, 1126-33 (2011).

(23) Chen, Z., Liew, D. & Kwan, P. Effects of a HLA-B\*15:02 screening policy on antiepileptic drug use and severe skin reactions. *Neurology* **83**, 2077-84 (2014).

(24) Chung, W.H. *et al.* Medical genetics: a marker for Stevens-Johnson syndrome. *Nature* **428**, 486 (2004).

(25) Hung, S.I. *et al.* Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics* **16**, 297-306 (2006).

(26) Man, C.B. *et al.* Association between HLA-B\*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. *Epilepsia* **48**, 1015-8 (2007).

(27) Locharernkul, C. *et al.* Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\*1502 allele in Thai population. *Epilepsia* **49**, 2087-91 (2008).

(28) Mehta, T.Y. *et al.* Association of HLA-B\*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. *Indian J Dermatol Venereol Leprol* **75**, 579-82 (2009).

(29) Wu, X.T. *et al.* Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B\*1502 allele among patients in central China. *Epilepsy Behav* **19**, 405-8 (2010).

(30) Chang, C.C., Too, C.L., Murad, S. & Hussein, S.H. Association of HLA-B\*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. *Int J Dermatol* **50**, 221-4 (2011).

(31) Then, S.M., Rani, Z.Z., Raymond, A.A., Ratnaningrum, S. & Jamal, R. Frequency of the HLA-B\*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. *Asian Pac J Allergy Immunol* **29**, 290-3 (2011).

(32) Wang, Q. *et al.* Association between HLA-B\*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. *Seizure* **20**, 446-8 (2011).

(33) Zhang, Y. *et al.* Strong association between HLA-B\*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. *Eur J Clin Pharmacol* **67**, 885-7 (2011).

(34) Kulkantrakorn, K. *et al.* HLA-B\*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. *Pain Pract* **12**, 202-8 (2012).

(35) Shi, Y.W. *et al.* Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B\*1502? *Basic Clin Pharmacol Toxicol* **111**, 58-64 (2012).

(36) Neuman, M.G., Cohen, L., Nanau, R.M. & Hwang, P.A. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. *Transl Res* **159**, 397-406 (2012).

(37) Amstutz, U. *et al.* HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. *Clin Pharmacol Ther* **94**, 142-9 (2013).

(38) He, X.J. *et al.* Association between the HLA-B\*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. *Pharmacol Rep* **65**, 1256-62 (2013).

(39) Cheung, Y.K., Cheng, S.H., Chan, E.J., Lo, S.V., Ng, M.H. & Kwan, P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. *Epilepsia* **54**, 1307-14 (2013).

(40) Lin, Y.T. *et al.* A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. *J Eur Acad Dermatol Venereol* **27**, 356-64 (2013).

(41) Aggarwal, R., Sharma, M., Modi, M., Garg, V.K. & Salaria, M. HLA-B \* 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population. *Hum Immunol* **75**, 1120-2 (2014).

(42) Chong, K.W. *et al.* Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B\*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. *Arch Dis Child* **99**, 581-4 (2014).

(43) Khor, A.H., Lim, K.S., Tan, C.T., Wong, S.M. & Ng, C.C. HLA-B\*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. *Epilepsia* **55**, e120-4 (2014).

(44) Kwan, P.K., Ng, M.H. & Lo, S.V. Association between HLA-B\*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study. *Hong Kong Med J* **20 Suppl 7**, 16-8 (2014).

(45) Sun, D. *et al.* Association of HLA-B\*1502 and \*1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. *J Huazhong Univ Sci Technolog Med Sci* **34**, 146-50 (2014).

(46) Genin, E. *et al.* HLA-A\*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. *Pharmacogenomics J* **14**, 281-8 (2014).

(47) Hsiao, Y.H. *et al.* Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. *J Dermatol Sci* **73**, 101-9 (2014).

(48) Toh, D.S. *et al.* Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. *Pharmacogenomics J* **14**, 316-21 (2014).

(49) Wang, W., Hu, F.Y., Wu, X.T., An, D.M., Yan, B. & Zhou, D. Genetic predictors of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by aromatic antiepileptic drugs among the Chinese Han population. *Epilepsy Behav* **37**, 16-9 (2014).

(50) Nguyen, D.V. *et al.* HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. *Asia Pac Allergy* **5**, 68-77 (2015).

(51) Yang, F. *et al.* Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans. *J Investig Dermatol Symp Proc* **17**, 29-31 (2015).

(52) Teh, L.K. *et al.* Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B\*15:02. *J Pharm Pharm Sci* **19**, 147-60 (2016).

(53) Alfirevic, A., Jorgensen, A.L., Williamson, P.R., Chadwick, D.W., Park, B.K. & Pirmohamed, M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. *Pharmacogenomics* **7**, 813-8 (2006).

(54) Kashiwagi, M. *et al.* Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. *J Dermatol* **35**, 683-5 (2008).

(55) Kaniwa, N. *et al.* HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics* **9**, 1617-22 (2008).

(56) Kano, Y., Hirahara, K., Asano, Y. & Shiohara, T. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. *Acta Derm Venereol* **88**, 616-8 (2008).

(57) Ikeda, H. *et al.* HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. *Epilepsia* **51**, 297-300 (2010).

(58) Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S. & Morita, E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. *J Dermatol* **39**, 594-601 (2012).

(59) Park, H.J. *et al.* HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. *Yonsei Med J* **57**, 118-26 (2016).

(60) Li, L.J., Hu, F.Y., Wu, X.T., An, D.M., Yan, B. & Zhou, D. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. *Epilepsy Res* **106**, 296-300 (2013).

(61) Lonjou, C. *et al.* A marker for Stevens-Johnson syndrome ...: ethnicity matters. *Pharmacogenomics J* **6**, 265-8 (2006).

(62) Odueyungbo, M.A., Sheehan, M.P. & Haggstrom, A.N. HLA-B\*1502 allele associated with carbamazepine-induced epidermal necrolysis. *Arch Dermatol* **146**, 1437-8 (2010).

(63) Elzagallaai, A.A., Garcia-Bournissen, F., Finkelstein, Y., Bend, J.R., Rieder, M.J. & Koren, G. Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han-Chinese child with a positive HLA-B\*1502 and negative in vitro toxicity assays: evidence for different pathophysiological mechanisms. *J Popul Ther Clin Pharmacol* **18**, e1-9 (2011).

(64) Wang, J., Zhang, J., Wu, X., Yu, P. & Hong, Z. HLA-B\*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. *J Int Med Res* **40**, 377-82 (2012).

(65) Techasatian, L., Panombualert, S., Uppala, R. & Jetsrisuparb, C. Carbamazepine-Induced Incomplete Stevens-Johnson Syndrome: Report of a Case in Children without Mycoplasma pneumoniae Infection. *J Med Assoc Thai* **98 Suppl 7**, S243-7 (2015).

(66) Tan, J.C., Murrell, D.F. & Hersch, M.I. Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. *J Clin Neurosci* **22**, 1992-3 (2015).

(67) Bellon, T. *et al.* The HLA-B\*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome. *Pharmacogenomics* **17**, 541-5 (2016).

(68) Chen, C.B. *et al.* Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. *Neurology* **88**, 78-86 (2017).

(69) Hu, F.Y., Wu, X.T., An, D.M., Yan, B., Stefan, H. & Zhou, D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B\*1502 allele in Chinese Han population. *Seizure* **20**, 160-2 (2011).

(70) He, N. *et al.* Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. *Seizure* **21**, 614-8 (2012).

(71) Lv, Y.D. *et al.* The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. *BMC Neurol* **13**, 75 (2013).

(72) Wang, W., Hu, F.Y., Wu, X.T., An, D.M., Yan, B. & Zhou, D. Genetic susceptibility to the cross-reactivity of aromatic antiepileptic drugs-induced cutaneous adverse reactions. *Epilepsy Res* **108**, 1041-5 (2014).

(73) Chen, Y.C., Chu, C.Y. & Hsiao, C.H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B\*1502 genotype. *J Eur Acad Dermatol Venereol* **23**, 702-3 (2009).

(74) Hung, S.I. *et al.* Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. *Pharmacogenomics* **11**, 349-56 (2010).

(75) Shankarkumar, U., Shah, K.N. & Ghosh, K. Letter: HLA B\*1502 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India. *Epilepsia* **50**, 1837-8 (2009).

(76) Lichtenfels, M. *et al.* HLA restriction of carbamazepine-specific T-Cell clones from an HLA-A\*31:01-positive hypersensitive patient. *Chem Res Toxicol* **27**, 175-7 (2014).

(77) McCormack, M. *et al.* HLA-A\*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med* **364**, 1134-43 (2011).

(78) Ozeki, T. *et al.* Genome-wide association study identifies HLA-A\*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet* **20**, 1034-41 (2011).

(79) Shirzadi, M., Thorstensen, K., Helde, G., Moen, T. & Brodtkorb, E. Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study. *Epilepsy Res* **118**, 5-9 (2015).

(80) Fricke-Galindo, I. *et al.* HLA-A\*02:01:01/-B\*35:01:01/-C\*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. *Pharmacogenomics* **15**, 1881-91 (2014).

(81) Song, J.S., Kang, E.S., Joo, E.Y., Hong, S.B., Seo, D.W. & Lee, S.Y. Absence of HLA-B\*1502 and HLA-A\*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash: a preliminary study. *Ann Lab Med* **34**, 372-5 (2014).

(82) Mizumoto, K., Sumikawa, Y., Niihara, H. & Morita, E. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A\*3101. *J Dermatol* **39**, 791-2 (2012).

(83) Anjum, N., Polak, M.E., Ardern-Jones, M. & Cooper, H.L. Presence of the HLA-A\*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepine. *Clin Exp Dermatol* **39**, 307-9 (2014).

(84) Segert, H., Sternberg, J., Stucker, M. & Gambichler, T. Carbamazepine-induced HLA-A\*3101 associated hypersensitivity syndrome mimicking mycosis fungoides. *J Eur Acad Dermatol Venereol* **30**, e154-e5 (2016).

(85) Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M. & Barton, G.J. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics* **25**, 1189-91 (2009).